Handelsbanken Fonder AB Has $2.96 Million Stake in Catalent, Inc. (NYSE:CTLT)

Handelsbanken Fonder AB grew its position in Catalent, Inc. (NYSE:CTLT) by 19.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,900 shares of the company’s stock after purchasing an additional 7,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Catalent were worth $2,962,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of CTLT. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent during the 2nd quarter worth about $42,000. Mather Group LLC. bought a new stake in shares of Catalent during the 1st quarter valued at about $52,000. Longfellow Investment Management Co. LLC grew its stake in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC increased its holdings in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares in the last quarter. Finally, Sound Income Strategies LLC increased its holdings in Catalent by 4,466.7% in the first quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock worth $77,000 after purchasing an additional 1,340 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CTLT shares. Barclays raised their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, StockNews.com started coverage on Catalent in a research note on Friday, October 4th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to data from MarketBeat.com, Catalent currently has an average rating of “Hold” and an average price target of $59.83.

Insider Activity at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,410 shares of company stock valued at $732,680 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Catalent Price Performance

Shares of NYSE CTLT opened at $60.75 on Wednesday. The stock has a market cap of $10.99 billion, a price-to-earnings ratio of -9.96, a PEG ratio of 2.32 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20. The firm’s 50-day simple moving average is $59.96 and its 200 day simple moving average is $57.56.

Catalent (NYSE:CTLT) last announced its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. As a group, research analysts anticipate that Catalent, Inc. will post 0.85 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.